FDA Plans Generative AI Medical Device Rules
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- FDA's Digital Health Center of Excellence is developing a plan to regulate medical devices that use generative artificial intelligence, with formal policy guidance documents forthcoming.
- Rick Abramson, director of the Digital Health Center of Excellence, confirmed the effort in an interview with STAT, calling formal policy guidance the agency's stated goal.
- Abramson said the AI ecosystem 'is expecting clarity' and that the FDA 'seeks to provide that clarity,' framing the guidance push as a response to industry demand.
- The planned guidance will include both broad generative AI guidance overall and 'narrowly constructed specialty guidance' on particular generative AI topics of 'special interest or special complexity,' per Abramson.
- The reporting comes as an exclusive to STAT+ subscribers, with the outlet positioned as the source breaking the FDA's regulatory roadmap for generative AI medical devices.
Why it matters: Medical device developers building on generative AI have operated without clear FDA parameters, slowing product roadmaps and compliance strategies. Abramson explicitly acknowledged industry demand for clarity and telegraphed not one but two tiers of guidance — broad plus topic-specific — meaning companies should expect rulemaking that addresses both general use cases and narrow high-complexity applications, not a single catch-all document.
Ask SkimNews
